ConductScience.org, home

Paper24311643

Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

Karajannis MA and 13 others. Neuro Oncol, 2014. Cited by 93 papers, by iCite.

Cite this record

ConductScience Library. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Papers, record 24311643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24311643

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
PubMed
Journal
Neuro Oncol
PubMed
Year
2014
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
93
iCite
Relative citation ratio, by iCite
2.87
iCite
Revised in PubMed
2026-03-01
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Karajannis MAMatthias A
2Legault GGeneviève
3Hagiwara MMari
4Giancotti FGFilippo G
5Filatov AAlexander
6Derman AAnna
7Hochman TTsivia
8Goldberg JDJudith D
9Vega EEmilio
10Wisoff JHJeffrey H
11Golfinos JGJohn G
12Merkelson AAmanda
13Roland JTJ Thomas
14Allen JCJeffrey C

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Neurofibromatosis 2Major topic
Neuroma, AcousticMajor topic
SirolimusMajor topic
Adolescent
Adult
Child
Disease Progression
Everolimus
Female
Follow-Up Studies
Humans
Magnetic Resonance Imaging
Male
Neoplasm Staging
Prognosis
Prospective Studies
Survival Rate
Young Adult

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30CA016087NIH

Source NIH RePORTER

Download CSV of grants

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116791048The natural history of vestibular schwannoma.Otol Neurotol2006https://conductscience.org/library/papers/16791048PubMed
217947729Phase I study of everolimus in pediatric patients with refractory solid tumors.J Clin Oncol2007https://conductscience.org/library/papers/17947729PubMed
32702835Optimal two-stage designs for phase II clinical trials.Control Clin Trials1989https://conductscience.org/library/papers/2702835PubMed
419671848Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.Clin Cancer Res2009https://conductscience.org/library/papers/19671848PubMed
521659604The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.Science2011https://conductscience.org/library/papers/21659604PubMed
622482125Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.EMBO Rep2012https://conductscience.org/library/papers/22482125PubMed
7713519Speech-discrimination scores modeled as a binomial variable.J Speech Hear Res1978https://conductscience.org/library/papers/713519PubMed
816371857Using audiometric thresholds and word recognition in a treatment study.Otol Neurotol2006https://conductscience.org/library/papers/16371857PubMed
919451229Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.Mol Cell Biol2009https://conductscience.org/library/papers/19451229PubMed
1016121974Systematic review of the natural history of vestibular schwannoma.J Neurosurg2005https://conductscience.org/library/papers/16121974PubMed
1119587327Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.N Engl J Med2009https://conductscience.org/library/papers/19587327PubMed
1221157483mTOR: from growth signal integration to cancer, diabetes and ageing.Nat Rev Mol Cell Biol2011https://conductscience.org/library/papers/21157483PubMed
1315354016Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.Otol Neurotol2004https://conductscience.org/library/papers/15354016PubMed
1419451225NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.Mol Cell Biol2009https://conductscience.org/library/papers/19451225PubMed
1522426462Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.Mol Cancer Res2012https://conductscience.org/library/papers/22426462PubMed
1622503123Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.J Neurosurg2012https://conductscience.org/library/papers/22503123PubMed
1719402072Targeting mTOR in renal cell carcinoma.Cancer2009https://conductscience.org/library/papers/19402072PubMed
1821659605Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling.Science2011https://conductscience.org/library/papers/21659605PubMed
197676998Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety.AJR Am J Roentgenol1995https://conductscience.org/library/papers/7676998PubMed
2021306238Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med2011https://conductscience.org/library/papers/21306238PubMed

See all 33 referencesDownload CSV of references

Cited by65

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.

PMIDTitleJournalYearIn PapersSource
42958385Divergent Schwann cell-immune cell trajectories across vestibular schwannoma subtypes mirror nerve injury-repair programs.J Neuroinflammation2026https://conductscience.org/library/papers/42958385PubMed
42272870T-cell-targeted immunotherapy in neurofibromatosis type 2-related vestibular schwannoma: current evidence and future direction.Brain Commun2026https://conductscience.org/library/papers/42272870PubMed
42142209A review of targeted therapies for NF2-related vestibular schwannoma: molecular pathogenesis, emerging therapeutics, and future clinical horizons.J Neurooncol2026https://conductscience.org/library/papers/42142209PubMed
41929036Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies.bioRxiv2026https://conductscience.org/library/papers/41929036PubMed
41899444Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions-A Scoping Review.Curr Issues Mol Biol2026https://conductscience.org/library/papers/41899444PubMed
41893038Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review.J Pers Med2026https://conductscience.org/library/papers/41893038PubMed
41814021Emerging systemic treatment strategies for vestibular schwannoma.J Neurooncol2026https://conductscience.org/library/papers/41814021PubMed
41565922Diverse NF2 alterations in cranial schwannomas: a two-case series of germline whole-gene deletion and somatic in-frame deletion.Brain Tumor Pathol2026https://conductscience.org/library/papers/41565922PubMed
41417846Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN-Associated and Sporadic NF2-Deficient Meningiomas.Cancer Res Commun2026https://conductscience.org/library/papers/41417846PubMed
40575410Phase II study of axitinib in patients with NF2-related schwannomatosis and progressive vestibular schwannomas.Neurooncol Adv2025https://conductscience.org/library/papers/40575410PubMed
40343504Multiplatform molecular analyses reveal two molecular subgroups of NF2-related schwannomatosis vestibular schwannomas with distinct tumour microenvironment and therapeutic vulnerabilities.Acta Neuropathol2025https://conductscience.org/library/papers/40343504PubMed
39022647From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas.Neurooncol Adv2024https://conductscience.org/library/papers/39022647PubMed
38936103Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.Eur J Cancer2024https://conductscience.org/library/papers/38936103PubMed
38879686NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.NPJ Precis Oncol2024https://conductscience.org/library/papers/38879686PubMed
38760612Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions.Oncol Ther2024https://conductscience.org/library/papers/38760612PubMed
38372904Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.J Neurooncol2024https://conductscience.org/library/papers/38372904PubMed
38216553Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state.Nat Commun2024https://conductscience.org/library/papers/38216553PubMed
38058737Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma.Mol Ther Methods Clin Dev2023https://conductscience.org/library/papers/38058737PubMed
37906356Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis.Curr Oncol Rep2023https://conductscience.org/library/papers/37906356PubMed
37706198A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis.Neurooncol Adv2023https://conductscience.org/library/papers/37706198PubMed

See all 65 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
NF24771PubTator's text mininghttps://conductscience.org/library/genes/4771NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24311643

GET https://conductscience.org/api/papers/v1/24311643/references?page=2